JMP Securities Maintains Athira(ATHA.US) With Hold Rating
JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)
Athira Pharma Analyst Ratings
Mizuho Downgrades Athira Pharma to Neutral, Lowers Price Target to $0.5
Mizuho Securities Downgrades Athira(ATHA.US) to Hold Rating, Cuts Target Price to $0.5
Jefferies Maintains Athira(ATHA.US) With Hold Rating, Cuts Target Price to $0.5
JMP Securities Maintains Athira(ATHA.US) With Hold Rating
Athira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical Progress
Mizuho Securities Maintains Athira(ATHA.US) With Buy Rating, Announces Target Price $5
Athira Pharma Cut to Neutral From Buy by BTIG
Athira Pharma Analyst Ratings
Stifel Maintains Athira(ATHA.US) With Hold Rating, Maintains Target Price $4
JMP Securities Downgrades Athira(ATHA.US) to Hold Rating
BTIG Downgrades Athira(ATHA.US) to Hold Rating
BTIG Downgrades Athira Pharma (ATHA) to a Hold
Rodman & Renshaw Initiates Athira(ATHA.US) With Buy Rating, Announces Target Price $22
Athira Pharma Analyst Ratings
Rodman & Renshaw Initiates Athira Pharma at Buy With $22 Price Target
JMP Securities Maintains Athira(ATHA.US) With Buy Rating, Maintains Target Price $19
Buy Rating Affirmed for Athira Pharma Amid Positive LIFT-AD Trial Prospects and Expanding Pipeline
No Data
No Data